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Introduction: Surgical procedures in von Willebrand disease (VWD) patients may require prophylactic treatment
with exogenous von Willebrand factor (VWF) and coagulation factor VIII (FVIII) to prevent excessive bleeding.
Wilate® is a plasma-derived, double virus-inactivated, highly purified, freeze-dried VWF/FVIII concentrate,
containing both factors in a physiological activity ratio of 1:1. Aim: To investigate the efficacy and safety of
wilate® in maintaining haemostasis in VWD patients undergoing surgical procedures. Methods: This prospective,
open-label multinational clinical study documents 28 individuals who underwent 30 surgical procedures managed
with wilate®. Twenty-one patients had VWD Type 3, and 21 surgeries were major. Efficacy was assessed intra-
and postoperatively by the surgeon and investigator, respectively, and adjudicated by an Independent Data
Monitoring Committee, using an objective scale based on blood loss, transfusion requirements and postoperative
bleeding and oozing. Treatment success (primary endpoint) was determined using a composite assessment
algorithm and was formally assessed. Results: Surgical prophylaxis with wilate® was successful in 29 of 30
procedures. The overall rate of success was 96.7% (98.75% CI: 0.784, 1.000). All 21 surgeries in patients with
VWD Type 3 were managed successfully. There was no accumulation of VWF or FVIII after multiple dosing, and
no thromboembolic events or inhibitors to VWF or FVIII were observed. Conclusions: Wilate® demonstrated
effective prevention and treatment of bleeding in inherited VWD patients undergoing surgery, with no clinically
significant safety concerns.
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Introduction
von Willebrand disease (VWD) is the most common
inherited bleeding disorder with a prevalence estimated
to range from 1 to 100 in 10 000 [1]. VWD is caused
by quantitative (Types 1 and 3) or qualitative (Type 2)
deficiency in von Willebrand factor (VWF) and is mark-
edly heterogeneous in type and severity [1–4]. Surgical
procedures in patients with VWD can be associated
with a life-threatening risk of excessive bleeding and
may require prophylactic treatment with a combined
VWF/FVIII concentrate [5]. Dosing of VWF/FVIII con-
centrates for surgical haemostasis depends on disease
severity and surgery type [6]. Several prospective and
retrospective studies have demonstrated the haemo-
static effect of VWF/FVIII-containing concentrates in
surgical procedures [5,7–14]. Although rare, repeated
administrations of VWF/FVIII products, as often
needed during surgery, have been associated with
thrombotic events linked to abnormally high plasma
levels of FVIII coagulant activity (FVIII:C) or VWF ris-
tocetin cofactor activity (VWF:RCo) [15].
Wilate® is a double virus-inactivated, plasma-
derived concentrate with the native VWF and FVIII
complex in a physiological 1:1 activity ratio [7,16–
18]. The efficacy, safety and tolerability of wilate® in
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the prevention and treatment of bleeding in adults and
children with VWD have been reported in several
prospective clinical trials [7,8,19–21], which included
surgical procedures. This current study (WONDERS)
investigated the clinical efficacy and safety of wilate®
in the prevention and treatment of surgical bleeding,
under well-defined, stringent protocol-driven and cen-
trally monitored conditions, in patients with inherited
VWD.
Methods
Study design
A prospective, open-label, multinational, phase III
clinical study was performed in paediatric and adult
patients with inherited VWD undergoing surgery to
evaluate the haemostatic efficacy and safety of wilate®
in maintaining intra- and postoperative haemostasis in
surgical procedures (ClinicalTrials.gov Identifier:
NCT01365546). The study originally planned to
examine up to 41 surgical procedures. A single interim
analysis was planned after 30 procedures, with the
possibility for early study termination if predefined
success criteria were achieved. Early success was
defined by a two-sided 98.75% confidence interval
(CI) for the overall success rate of >0.60 (equivalent
to ≥25 successes in 30 procedures). The interim analy-
sis showed that the prespecified success rate for study
termination was reached after 30 procedures.
Patients could have multiple independent surgeries
that were counted as separate surgical events. Patients
were monitored for 30 days from the start of each
surgery or until discharge, whichever came later. The
study was conducted in accordance with the ethical
principles of the Declaration of Helsinki, International
Conference on Harmonisation Good Clinical Practice
guidelines, and national regulatory requirements [22].
The final protocol was reviewed and approved by the
responsible regulatory authorities and institutional
ethics committees.
Enrolment criteria
The study enrolled males or females aged ≥6 years
with inherited VWD (any type) requiring a VWF/FVIII
concentrate to cover surgical procedures. Patients were
excluded if they had any other known coagulation dis-
order, had received a VWF/FVIII-containing product
within 3 days of the screening visit, had any known
inhibitor activity against VWF or FVIII and if continu-
ous infusion was planned. Additional exclusion crite-
ria included: active hepatic disease, known or
suspected hypersensitivity and receiving immune-mod-
ulating drugs at study start. Patients or parents/legal
guardians of paediatric patients provided full informed
consent.
Dosing
All doses were administered as a bolus intravenous infu-
sion. All patients received 60 IU kg1 of wilate® for the
in vivo recovery (IVR) investigation at study start to
calculate the recommended dosing for surgeries; addi-
tionally, the following guidelines were given:
Major surgery. A loading dose of 40–60 VWF:RCo
IU kg1 within 3 h of start of procedure was given to
achieve peak plasma VWF:RCo level of 100%. A
maintenance dose of 20–40 VWF:RCo IU kg1 or half
of the loading dose was given every 12–24 h. Trough
levels of VWF:RCo were to be maintained at >50%
for at least 6 days. At least two maintenance doses
were to be administered within the first 24 h after the
start of surgery.
Minor surgery. A loading dose of 30–60 VWF:RCo
IU kg1 within 3 h of start of procedure was given to
achieve peak plasma VWF: RCo level of 50%. A
maintenance dose of 20–40 VWF: RCo IU kg1 or
half of the loading dose was given every 12–24 h.
Trough levels of VWF: RCo were to be maintained at
>30% for at least 2 days.
These dosing recommendations were adjusted for
each patient using the results of the baseline IVR and
at the investigator’s discretion based on the clinical
situation. FVIII:C and VWF:RCo levels were moni-
tored throughout the treatment period, with the aim
of not exceeding a recommended maximum level of
250% FVIII:C and maintaining a recommended
trough level of at least 50% VWF:RCo for major
surgeries and 30% VWF:RCo for minor surgeries. No
VWF/FVIII preparations other than wilate® were to be
administered, except in emergency situations.
Efficacy and safety evaluations
Surgical prophylaxis. Efficacy of wilate® was assessed
by the surgeon at the end of each surgical procedure
(last suture) using a stringent and objective 4-point
efficacy scale (excellent, good, moderate or none)
based on blood loss and transfusion requirements dur-
ing surgery, and postoperatively by the investigator
based on postoperative bleeding and oozing, covering
the time period from the end of the procedure up to
24 h following the last wilate® infusion. In the event
of a discrepancy between surgeons’ and investigators’
assessments, falling into one of the categories marked
‘primary adjudication’ in Table 1, the classification of
success or failure was determined by the Independent
Data Monitoring Committee (IDMC).
Plasma levels of haemostatic parameters and IVR. IVR
of FVIII:C, VWF:RCo and von Willebrand factor anti-
gen (VWF:Ag) were determined at a central laboratory
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for all patients at the screening/baseline visit, and used to
calculate the recommended dosing (VWF:RCo). Plasma
levels of haemostatic parameters and IVRwere addition-
ally determined for every maintenance infusion 30 min
before and after every infusion. These plasma samples
were analysed locally for monitoring purposes and con-
firmed later by the central laboratory.
Safety. Clinical tolerability was assessed by monitor-
ing vital signs, laboratory parameters (including VWF
inhibitors and virus markers) and adverse events.
Statistics
The primary analysis focused on the overall propor-
tion of surgeries rated as successful (Table 1). For the
overall efficacy assessment, a CI of 98.75% was used,
and for the intra- and postoperative assessment, a CI
of 95% was used.
Results
Patient demographics
The study enrolled 39 individual patients (safety popu-
lation), of whom 28 individual patients underwent 30
surgeries (intent-to-treat [ITT] population). All 39
enrolled patients were included in the safety popula-
tion as all received an infusion of wilate® for IVR
determination, but not all underwent surgery. As the
prespecified criteria for success were met at the
interim analysis, the study was terminated early (after
30 surgeries). Demographic characteristics (ITT) are
shown in Table 2. Median (range) baseline levels of
VWF:RCo were 22.5 IU dL1 (3–38 IU dL1),
6.5 IU dL1 (4–9 IU dL ) and 0.0 IU dL1 (0–
10 IU dL1) for patients with VWD Type 1, Type 2
and Type 3, respectively. Median (range) baseline
levels of FVIII:C were 43.0 IU dL1 (2–65 IU dL1),
25.5 IU dL1 (21–30 IU dL1) and 1.0 IU dL1 (0–
39 IU dL1), respectively. Seven procedures were per-
formed in patients with VWD Type 1 (23.3%), two in
patients with VWD Type 2 (6.7%) and 21 in patients
with VWD Type 3 (70.0%). One patient with VWD
Type 1 and one with VWD Type 3 underwent two
surgeries.
Efficacy in surgical prophylaxis
Of the 30 surgical procedures, 21 were major and
nine were minor. Of the 21 procedures in VWD Type
3 patients, 17 (81.0%) were major. Major procedures
included orthopaedic (8), obstetric/gynaecological (5),
gastrointestinal (4), dental (2) and ear, nose and
throat (2) surgeries. Minor procedures included dental
(5), orthopaedic (2), ophthalmologic (1) and ear, nose
and throat (1) surgeries.
The overall success rate of wilate® treatment was
96.7% based on objective criteria and as adjudicated
by the IDMC (98.75% CI: 0.784, 1.000) (Table 3A).
Table 1. Composite assessment algorithm to determine the overall effectiveness of wilate treatment.
Intraoperative assessment
Postoperative assessment
Excellent Good Moderate None
Excellent Success Success Success Primary adjudication
Good Success Success Primary adjudication Failure
Moderate Success Primary adjudication Failure Failure
None Primary adjudication Failure Failure Failure
In the event of a discrepancy between surgeons’ and investigators’ assessments, falling into one of the categories marked ‘primary adjudication’, the classi-
fication of success or failure was determined by the IDMC. In addition, the IDMC conducted an independent and blinded adjudication of all haemostatic
efficacy results (‘secondary adjudication’), and the overall success (primary endpoint) was based on both the intra- and postoperative IDMC efficacy
assessments.
Table 2. Demographic and baseline clinical characteristics of ITT popula-
tion.
Parameters ITT population (N = 30*)
Age at screening (years)
Mean (SD) 38.3 (16.8)
Median (range) 36.0 (12–74)
Height (cm)
Mean (SD) 161.9 (11.2)
Median (range) 162.0 (141–187)
Weight (kg)
Mean (SD) 69.4 (23.6)
Median (range) 63.7 (39–126)
Gender, N (%)
Male 9 (30.0)
Female 21 (70.0)
Race, N (%)
White 18 (60.0)
Asian 12 (40.0)
VWD Type, N (%)
Type 1 7 (23.3)
Type 2 2 (6.7)
Type 3 21 (70.0)
Family history of VWD, N (%)
Yes 11 (36.7)
No 16 (53.3)
Unknown 3 (10.0)
VWF inhibitor activity, N (%)
Yes 0 (0)
No 30 (100)
N, number of surgeries.
*Two patients were enrolled in two surgeries each; therefore, there were
28 individual patients.
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The success rate was 100.0% for minor surgeries
(98.75% CI: 0.569, 1.000) and 95.2% for major surg-
eries (98.75% CI: 0.704, 1.000). The overall success
rate was 100.0% in VWD Type 3 (98.75% CI: 0.785,
1.000) and Type 2 (98.75% CI: 0.079, 1.000)
patients, and 85.7% in VWD Type 1 patients
(98.75% CI: 0.328, 0.999) (Table 3B). Only one pro-
cedure was considered non-successful due to an intra-
operative haemostatic efficacy rating of moderate by
both the surgeon and IDMC, and a postoperative effi-
cacy rating of good and moderate by the investigator
and IDMC, respectively. This VWD Type 1 patient
(baseline VWF:RCo plasma level: 21 IU dL1) under-
went left lumbar spine laminectomy (major surgery).
The blood loss observed was slightly greater (25 mL)
than the expected maximum in a patient with normal
haemostasis (20 mL). No transfusions or additional
doses of VWF/FVIII concentrate were needed for this
patient. Postoperatively, the patient developed bruising
and induration, and the wound had healed by the time
the patient was discharged. The investigator later
noted that these issues were due to an intraoperative
complication.
Dosing for surgical procedures
Exposure to wilate® during surgeries and the dosages
required are summarized in Table 4. For loading and
maintenance infusions, patients received wilate® for a
mean of 7.7 days (median: 7.0; range: 3–17), and
received a mean total cumulative dose of 293.1 IU
VWF:RCo kg1 (median: 270.6; range: 66–700). The
mean duration of major surgery was 9 days (median:
8.0; range: 4–17) and mean total cumulative dose was
368.9 IU kg1 (median: 360; range: 147–700). The
mean duration of minor surgery was 4.7 days (me-
dian: 4.0; range: 3–10) and the mean total cumulative
dose was 116.2 IU kg1 (median: 127.5; range: 66–
163). The mean daily doses administered over time
following major and minor surgeries are shown in
Fig. 1. Patients with VWD Type 3 had the longest
mean exposure time (8.8 days; median: 8.0; range: 4–
17) and received the highest mean cumulative doses
(330.7 IU VWF:RCo kg1; median: 340.4; range:
107–700). This was not unexpected as these patients
have the most severe form of VWD, and a higher pro-
portion of major surgeries were performed in VWD
Type 3 patients.
The mean total loading dose was 51.4 IU VWF:
RCo kg1 per infusion (median: 52.1; range: 27–77)
and the mean maintenance dose was 28.5 IU VWF:
RCo kg1 per infusion (median: 28.5; range: 8–63).
Intra- and postoperative blood loss and blood
transfusions
Intraoperative blood loss was lower than the maximal
expected in 28 of 30 procedures (mean [SD] difference
–294.9 [502.2] mL); maximal blood loss was higher
than expected during a lumbar laminectomy (25 mL
actual vs. 20 mL expected) and a partial amputation of
a big toe (50 mL actual vs. 30 mL maximal expected).
Greater postoperative bleeding and oozing than the
maximal expected was recorded during the lumbar
laminectomy and an ankle arthrodesis; the bleeding
was not excessive in either case and did not require
additional doses of wilate® or transfusions. Based on
the algorithm for overall efficacy (Table 1), only the
lumbar laminectomy was classified as a treatment fail-
ure in cases of higher than expected blood loss. Intraop-
erative transfusions were electively planned for five
patients undergoing major surgeries, but were only
required in two patients. In these patients, the mean
actual transfusion volume (287.5 mL) was lower than
Table 3. Haemostatic efficacy assessment by severity of surgery (A) and type of VWD (B).
(A) Efficacy assessment*
Surgery type
Minor (N = 9) Major (N = 21) All surgeries (N = 30)
Success
N (%) 9 (100) 20 (95.2) 29 (96.7)
Rate (98.75% CI) 1.000 (0.569, 1.000) 0.952 (0.704, 1.000) 0.967 (0.784, 1.000)
Failure†
N (%) 0 (0) 1 (4.8) 1 (3.3)
(B) Efficacy assessment*
VWD type
Type 1 (N = 7) Type 2 (N = 2) Type 3 (N = 21)
Success
N (%) 6 (85.7) 2 (100) 21 (100)
Rate (98.75% CI) 0.857 (0.328, 0.999) 1.000 (0.079, 1.000) 1.000 (0.785, 1.000)
Failure†
N (%) 1 (14.3) 0 (0) 0 (0)
N, number of surgeries.
*Derived overall assessment = Based on the derived overall assessment (derived from the intra- and postoperative assessment of the IDMC, based on
blood loss, transfusion requirements and postoperative bleeding and oozing).
†Primary adjudication.
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the mean expected volume (1190 mL). Aminocaproic
acid and tranexamic acid were planned and adminis-
tered intraoperatively in five patients.
Plasma levels of haemostatic parameters over time
FVIII:C, VWF:RCo and VWF:Ag plasma levels were
monitored throughout the postoperative period.
Figure 2 shows mean peak and trough levels over time
in all surgeries (Fig. 2a), major surgeries (Fig. 2b) and
minor surgeries (Fig. 2c). Mean plasma levels of
haemostatic parameters remained stable during main-
tenance dose administrations. While VWF:RCo trough
levels were sometimes low between maintenance
doses, FVIII levels were sufficient to maintain
haemostasis. Six patients had instances of FVIII:C val-
ues >250 IU dL1 (range: 256–395) during mainte-
nance infusions; however, in most cases, this
correlated with higher dosing, which was corrected by
decreasing the dose. No accumulation of FVIII:C was
observed over time and no thromboembolic events
occurred.
Table 4. Summary of wilate doses administered during the study.
Parameters Major Minor Total
Exposure days* N = 21 N = 9 N = 30
9.0  3.5 4.7  2.4 7.7  3.8
8.0 (4–17) 4.0 (3–10) 7.0 (3–17)
Total dose, IU VWF:RCo* N = 21 N = 9 N = 30
25 933 (12 257) 7389 (3090) 20 370 (13 452)
27 000 (11 000–60 000) 6500 (3000–13 000) 16 000 (3000–60 000)
Total dose, IU VWF:RCo kg1* N = 21 N = 9 N = 30
368.9  139.8 116.2  32.2 293.1  166.3
360.0 (147–700) 127.5 (66–163) 270.6 (66–700)
Preoperative loading dose, IU per procedure N = 21 N = 9 N = 30
4691 (2205) 2667 (1146) 4083 (2146)
4000 (3000–13 000) 3000 (1000–5000) 4000 (1000–13 000)
Preoperative loading dose, IU kg1 per procedure N = 21 N = 9 N = 30
67.7 (27.3) 41.9 (15.0) 60.0 (26.8)
61.4 (41–169) 37.5 (27–77) 57.3 (27–169)
Preoperative loading dose†, IU per infusion n = 26 n = 9 n = 35
3789 (1176) 2667 (1146) 3500 (1254)
4000 (2000–7000) 3000 (1000–5000) 3000 (1000–7000)
Preoperative loading dose†, IU kg1 per infusion n = 26 n = 9 n = 35
54.7 (10.1) 41.9 (15.0) 51.4 (12.6)
55.5 (36–69) 37.5 (27–77) 52.1 (27–77)
Maintenance dose, IU per infusion n = 214 n = 31 n = 245
2085 (1023) 1371 (670) 1994 (1012)
2000 (600–8000) 1000 (500–3000) 2000 (500–8000)
Maintenance dose, IU kg1 per infusion n = 214 n = 31 n = 245
29.6 (9.3) 21.6 (6.4) 28.5 (9.3)
30.0 (8–63) 20.6 (14–38) 28.5 (8–63)
N, number of surgeries; n, number of infusions.
*Includes wilate administrations for loading and maintenance infusions only.
†Three patients received two loading doses and one patient received three loading doses. These additional loading doses were not administered due to
insufficient efficacy of the initial dose, but due to delays in the start of surgery or to a presurgical procedure.
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Recovery investigations over time
The majority of IVR values for FVIII and VWF
were in the expected range over the entire study
period (Fig. 3). Several patients had IVR values
that were higher or lower than physiologically plau-
sible, but nearly all of these outliers were present at
only one or two time points, and could be
attributed to possible errors in the assay or sample
handling.
Safety and tolerability
The mean cumulative dose per procedure for the 30
surgical procedures (in 28 patients) was 24 653 IU
(739 590 IU overall). Of 262 exposure days to
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Fig. 2. Mean peak plasma VWF/FVIII levels post-dosing and mean trough plasma VWF/FVIII levels pre-dosing. Mean peak and trough plasma concentra-
tions of VWF and FVIII over time in the ITT population are shown by dose in all surgeries (a), major surgeries (b) and minor surgeries (c). Only the mainte-
nance infusions with values available for more than one patient are shown. Numbers at the top of each figure represent the number of patients contributing to
that particular time point. 0 = presurgery loading dose. Error bars represent the standard error of the mean.
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wilate®, 250 were for surgical prophylaxis. The dura-
tion of wilate® treatment following major and minor
surgery is shown in Fig. 4.
Eight non-serious adverse events in five patients
were considered to be probably related to treatment,
and included hypersensitivity, chest discomfort, feeling
hot, dizziness and decrease in blood pressure. All were
mild or moderate in intensity, and all resolved without
sequelae. One of these patients experienced moderate
hypersensitivity that led to discontinuation of wilate®
during the presurgery loading infusion. The patient
subsequently withdrew consent and received no fur-
ther wilate® infusions. The investigator/nurse noted
that the patient appeared extremely anxious and time-
conscious and that the symptoms were most likely
related to anxiety. Postoperative haematomas occurred
in four procedures (three patients); however, none
required evacuation.
There were no thromboembolic events and
antithrombotic agents were not administered to any
patients. No VWF or FVIII inhibitors or virus sero-
conversions were observed.
Discussion
This prospective study addressed the efficacy and
safety of wilate® in the maintenance of haemostasis in
patients with inherited VWD undergoing surgery. The
study used stringent, objective efficacy criteria to
assess efficacy during and after surgical procedures, as
well as blinded adjudication of all efficacy assessments
by the IDMC and statistical analysis, to provide a
conservative, unbiased efficacy assessment of wilate®.
The use of objective assessment criteria for surgical
prophylaxis in this study is in line with recently devel-
oped objective efficacy criteria in non-surgical settings
[23].
The success of wilate® in surgical prophylaxis was
established at the planned interim analysis in all but
one (29/30) surgical procedures. As the prespecified
success criteria were met, the study was terminated
early as recommended by the IDMC. The overall suc-
cess rate was 96.7% (98.75% CI: 0.784, 1.000). This
is particularly noteworthy in the light of the high per-
centage of major surgeries performed (70%) and that
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70% were in VWD Type 3. All procedures in Type 3
patients were successful. In addition, although the
number of paediatric procedures was low (three surg-
eries in three patients), efficacy was rated as excellent
or good in all procedures.
The overall haemostatic efficacy rate obtained in
this study is in line with a previous pooled analysis of
four prospective clinical trials that included evaluation
of wilate® efficacy during surgery [7]. In the pooled
analysis (53 rated procedures in 32 patients), efficacy
was excellent or good in 51 of 53 (96%) procedures.
Also consistent with the results from this study are
those reported in VWD patients receiving wilate® in
real-life, clinical settings in the UK [8,24]. Based on a
subjective 4-point scale, surgical efficacy of wilate® in
the UK cohort was rated excellent or good in 66 of
70 (94%) procedures (34 patients). Therefore, despite
the objective, more stringent efficacy criteria used in
this study, efficacy rates were similar to those reported
in studies using more subjective criteria.
A number of studies evaluating the efficacy of VWF/
FVIII concentrates other than wilate® in a surgical set-
ting have been published. In two prospective studies,
Humate-P® was deemed effective (excellent or good
overall efficacy) in 94.3% and 100% of 35 elective
surgeries and 42 urgent surgical procedures, respec-
tively [13,14]. The overall number of patients with
VWD Type 3 was much lower in these studies com-
pared with this study (37% and 21% vs. 70%),
although the proportion of major procedures was
comparable (71% and 60% vs. 70%). In a review of
several VWF/FVIII concentrates other than wilate®,
efficacy rates during surgery ranged from 91% to
100%, as assessed by mostly subjective criteria [10].
In this study, wilate® dosing was comparable or
lower than dosing reported for other concentrates in
VWD patients undergoing surgery. In this study,
patients received a median loading dose per infusion
of 52.1 IU VWF:RCo kg1 (range: 27–77) compared
with 82.3 IU VWF:RCo kg1 (range: 32.5–216.8)
with Humate-P® and 62.4 IU VWF:RCo kg1 (in-
terquartile range: 50.1–87.0) with Haemate® P
[12,13]. For maintenance infusions, in this study,
patients received a median of 28.5 IU VWF:RCo kg1
(range: 8–63), while in the studies with Humate-P®
and Haemate® P, median maintenance doses were
52.8 IU VWF:RCo kg1 (range: 24.2–196.5) and 38.9
to 46.8 IU VWF:RCo kg1, respectively [12,13].
Although rare, thromboembolic complications are a
concern in surgeries covered with any VWF/FVIII con-
centrate due to the potentially frequent and high doses
administered over a longer period and possible accu-
mulation of VWF and FVIII. Plasma levels of VWF
and FVIII remained stable during wilate® maintenance
dose administrations and no sustained FVIII accumu-
lation over time or thromboembolic events were
observed during this study. In contrast, accumulation
of FVIII has been observed in studies with other
VWF/FVIII concentrates [12,14]. In one study with
Humate-P®, a modest rise in FVIII:C was observed
over time in some patients, with nine patients experi-
encing FVIII:C >200 IU dL1 in 52 instances [14]. In
another study with Haemate® P, FVIII:C progressively
increased before each therapeutic/maintenance dose,
suggesting some accumulation of FVIII over time [12].
Additionally, one patient developed a pulmonary
embolism during the study, with a high FVIII:C
plasma level of 450 IU dL1 recorded the previous
day. The data in this study indicate that a product
with a 1:1 VWF to FVIII ratio can be easily dosed
using a FVIII haemostatic target. In addition, dosing
can be based on either VWF:RCo or FVIII:C IU as
observed plasma levels run in parallel after repeat dos-
ing. The parallel decay curves for VWF and FVIII
activity was predicted from the single-dose pharma-
cokinetics of wilate®, which was shown to be signifi-
cantly different from other VWF concentrates [17].
FVIII accumulation is not seen in these data, which
should reduce the issue of increased thrombogenicity
with multiple dosing that has been reported with other
VWF/FVIII concentrates. Moreover, using a FVIII
assay to predict VWF levels enables more convenient
monitoring. Given that peak FVIII:C plasma levels
were mostly between 125 and 150% and trough levels
between 75 and 100% during major surgeries, it is
likely that haemostasis could be achieved with 25–
30% lower doses of wilate® if FVIII:C was used as a
marker for adequacy of haemostasis instead of target-
ing presumed haemostatic levels of VWF:RCo. Such
an approach would avoid reaching unnecessarily high
levels of FVIII:C, which are implicated in increased
thrombotic risk, and in most cases would be easier to
perform and be potentially more reliable.
No treatment-related severe or serious adverse
events occurred in this study. Importantly, no cases of
VWF or FVIII inhibitors were observed and no virus
seroconversions occurred. We therefore conclude that
wilate® is well tolerated and effective in achieving sur-
gical haemostasis in patients with all types of VWD
with no accumulation of FVIII after repeat dosing.
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